Company Overview
Bilcare Limited provides pharmaceutical packaging research solutions in India and internationally. The company offers aluminum foils, polymer films, and anti-counterfeiting packaging solutions for solid dosage pharmaceutical products and other applications; and blister films and foils, lidding foils, cr foils, and laminates. It also engages in the provision of clinical trial supplies, clinical trial management, and brand protection technologies services; and research and development services comprising formulation stability studies, blister/foil design and development, pharma brand innovation, analytical research and market study, and packaging trials and audit. Bilcare Limited was incorporated in 1987 and is headquartered in Pune, India.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹734.00 Cr (-6.9% YoY); net profit ₹-17.00 Cr.
- Trailing 12 Months Year-on-year growth — revenue -6.9%, earnings +1597.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -11.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -11.14% |
| 1 Year: | -6.85% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 1,597.80% |
Stock Price Performance
| 1 Year: | +50.47% |
| 6 Months: | - |
| 3 Months: | +52.58% |
| 1 Month: | +56.49% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)65.46 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 131.3.
- Revenue declined at -11.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 233.59 Cr | 182.25 Cr | 189.92 Cr | 174.94 Cr | 200.07 Cr | 194.14 Cr | 201.74 Cr | 198.13 Cr | 194.03 Cr | 186.36 Cr | 178.20 Cr | 181.32 Cr | 187.66 Cr |
| Operating Expenses | 219.16 Cr | 168.79 Cr | 173.22 Cr | 157.69 Cr | 208.33 Cr | 175.20 Cr | 194.09 Cr | 187.47 Cr | 186.35 Cr | 175.29 Cr | 174.78 Cr | 168.31 Cr | 170.73 Cr |
| Operating Income | 5.13 Cr | 2.96 Cr | 6.22 Cr | 6.68 Cr | -21.66 Cr | 7.42 Cr | -3.39 Cr | -1.08 Cr | 3.02 Cr | -49.00 L | -8.81 Cr | 8.00 Cr | 12.15 Cr |
| EBITDA | 14.43 Cr | 13.46 Cr | 16.70 Cr | 17.25 Cr | -8.26 Cr | 18.94 Cr | 7.65 Cr | 10.66 Cr | 7.68 Cr | 11.07 Cr | 3.42 Cr | 13.01 Cr | 16.93 Cr |
| Interest Expense | 11.38 Cr | 19.00 Cr | 19.66 Cr | 20.54 Cr | 22.59 Cr | 20.85 Cr | 23.68 Cr | 19.48 Cr | 18.68 Cr | 18.55 Cr | 19.06 Cr | 17.04 Cr | 17.69 Cr |
| Pretax Income | 225.04 Cr | -13.29 Cr | -12.88 Cr | -10.10 Cr | -35.43 Cr | -9.69 Cr | -33.09 Cr | -27.03 Cr | 5.50 Cr | -12.96 Cr | -23.55 Cr | -5.70 Cr | 6.92 Cr |
| Tax Provision | 146.77 Cr | 15.02 L | 69.04 L | -3.44 Cr | 15.76 Cr | -5.33 Cr | 3.16 Cr | 10.79 Cr | -6.56 Cr | 3.20 Cr | 23.08 L | -18.98 L | -93.00 L |
| Net Income | 78.28 Cr | -13.14 Cr | -12.19 Cr | -13.54 Cr | -19.67 Cr | -15.02 Cr | -29.93 Cr | -16.24 Cr | 12.06 Cr | -9.76 Cr | -23.32 Cr | -5.89 Cr | 7.85 Cr |
| Diluted EPS | 19.63 | -3.36 | -3.22 | -2.91 | -4.63 | -2.71 | -6.81 | -3.04 | 7.47 | -1.61 | -5.25 | 0.41 | 5.68 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,692.00 Cr | 2,603.00 Cr | 2,633.00 Cr | 2,778.00 Cr | 2,997.00 Cr | 1,827.00 Cr | 623.00 Cr | 845.00 Cr | 982.00 Cr | 747.00 Cr | 788.00 Cr | 734.00 Cr |
| Operating Expenses | 2,506.00 Cr | 2,396.00 Cr | 2,443.00 Cr | 2,617.00 Cr | 2,827.00 Cr | 1,782.00 Cr | 572.00 Cr | 784.00 Cr | 925.00 Cr | 708.00 Cr | 743.00 Cr | 689.00 Cr |
| Operating Income | -5.00 Cr | 43.00 Cr | 13.00 Cr | -255.00 Cr | -208.00 Cr | -194.00 Cr | 5.00 Cr | 21.00 Cr | 19.00 Cr | -6.00 Cr | -1.00 Cr | 24.00 Cr |
| EBITDA | 186.00 Cr | 207.00 Cr | 190.00 Cr | 161.00 Cr | 170.00 Cr | 45.00 Cr | 51.00 Cr | 60.00 Cr | 57.00 Cr | 39.00 Cr | 45.00 Cr | 44.00 Cr |
| Interest Expense | 236.00 Cr | 151.00 Cr | 176.00 Cr | 249.00 Cr | 283.00 Cr | 174.00 Cr | 76.00 Cr | 69.00 Cr | 60.00 Cr | 82.00 Cr | 82.00 Cr | 72.00 Cr |
| Pretax Income | -232.00 Cr | -194.00 Cr | -56.00 Cr | -207.00 Cr | -433.00 Cr | -114.00 Cr | -25.00 Cr | -4.00 Cr | 196.00 Cr | -72.00 Cr | -71.00 Cr | -21.00 Cr |
| Tax Provision | 16.24 Cr | 112.52 Cr | -23.52 Cr | 8.28 Cr | -21.65 Cr | 14.82 Cr | 13.75 Cr | -12.00 L | 145.04 Cr | 12.96 Cr | 14.91 Cr | 3.99 Cr |
| Net Income | -216.00 Cr | -82.00 Cr | -80.00 Cr | -199.00 Cr | -453.00 Cr | -99.00 Cr | -11.00 Cr | -4.00 Cr | 50.00 Cr | -59.00 Cr | -56.00 Cr | -17.00 Cr |
| Diluted EPS | -91.76 | -36.04 | -35.91 | -85.43 | -193.28 | -43.97 | -8.95 | -5.35 | 6.39 | -14.12 | -12.23 | 0.73 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 4,340.00 Cr | 3,620.00 Cr | 3,457.00 Cr | 3,402.00 Cr | 3,087.00 Cr | 1,112.00 Cr | 1,064.00 Cr | 1,127.00 Cr | 1,593.00 Cr | 1,568.00 Cr | 1,417.00 Cr | 843.00 Cr |
| Total Equity | 1,097.00 Cr | 713.00 Cr | 614.00 Cr | 400.00 Cr | -69.00 Cr | 109.00 Cr | 87.00 Cr | 76.00 Cr | 531.00 Cr | 498.00 Cr | 469.00 Cr | 197.00 Cr |
| Total Debt | 2,311.00 Cr | 2,122.00 Cr | 2,014.00 Cr | 2,089.00 Cr | 2,270.00 Cr | 707.00 Cr | 677.00 Cr | 690.00 Cr | 639.00 Cr | 756.00 Cr | 682.00 Cr | 620.00 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -315.00 Cr | 177.00 Cr | 300.00 Cr | 98.00 Cr | 206.00 Cr | 256.00 Cr | 72.00 Cr | 41.00 Cr | -7.00 Cr | 62.00 Cr | 85.00 Cr | 128.00 Cr |
| Investing Cash Flow | 247.00 Cr | -358.00 Cr | -129.00 Cr | -203.00 Cr | -104.00 Cr | 1,309.00 Cr | 2.00 Cr | -4.00 Cr | 36.00 Cr | -106.00 Cr | 81.00 Cr | -6.00 Cr |
| Financing Cash Flow | 119.00 Cr | 149.00 Cr | -155.00 Cr | 91.00 Cr | -103.00 Cr | -1,600.00 Cr | -83.00 Cr | -55.00 Cr | -19.00 Cr | 36.00 Cr | -169.00 Cr | -132.00 Cr |
| Capital Expenditure | 241.00 Cr | -189.00 Cr | -135.00 Cr | -213.00 Cr | -115.00 Cr | 1,313.00 Cr | -3.00 Cr | -4.00 Cr | 18.00 Cr | -96.00 Cr | 55.00 Cr | -8.00 Cr |
| Free Cash Flow | -74.00 Cr | -12.00 Cr | 165.00 Cr | -115.00 Cr | 91.00 Cr | 1,569.00 Cr | 69.00 Cr | 37.00 Cr | 11.00 Cr | -34.00 Cr | 140.00 Cr | 120.00 Cr |
| Net Change in Cash | 50.00 Cr | -32.00 Cr | 16.00 Cr | -13.00 Cr | -1.00 Cr | -35.00 Cr | -9.00 Cr | -18.00 Cr | 10.00 Cr | -7.00 Cr | -3.00 Cr | -10.00 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -0.2% | 1.7% | 0.5% | -9.2% | -6.9% | -10.6% | 0.8% | 2.5% | 1.9% | -0.8% | -0.1% | 3.3% |
| Net Margin % | -8.0% | -3.2% | -3.0% | -7.2% | -15.1% | -5.4% | -1.8% | -0.5% | 5.1% | -7.9% | -7.1% | -2.3% |
| ROE % | -19.7% | -11.5% | -13.0% | -49.8% | 656.5% | -90.8% | -12.6% | -5.3% | 9.4% | -11.8% | -11.9% | -8.6% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BI
Indonesian Stocks Rally as Destry’s BI Appointment Boosts Confidence - Jakarta Globe
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOeWNNWkkyYnFtb3AzWkxBazFSb1c1bzZpZzJPSzd2Q2swT1UzZENCTTRVb3gzMC1iNldYQ19sWGtUcFk0enlDd0NyVVFtVVlaZEhBUU54NEtqYkFMTFROZkRLRWJxblpKTGhvZEhUTmhCVmlaUktnQXdudUM2UjY5eXZXbXRDT2V5ZFlLam…
South Korea’s rookie investors lose small fortunes amid AI stocks frenzy - Al Jazeera
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOUnNUNTNYeHFLcTVvN0VZNTBkbXpHT24tS2FveUNYZ3AtTEpXV0NUWHhmdmV6Yy1wT1lfMWpjbWRNaHR6ZVRXNUt2UWNmVGhIR2pEdnBYNHlmMGNXLU11NEltNjZySVo1Y1FiOFBBcGhha194ak5VX2JQd3Z1Z3RZUDRVZFRpV1Jlb1AyZF…
Alphabet steamrolled BI's stock bracket. Here are 4 things your picks revealed. - Business Insider
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPLWN0bUl5YlNSdXg3ajRXVzA2UnFnQzVoSnItMUE0bmlUMExWNS1sOFpLQ2lBLWxDRFFadllRNkpnRzFXYW91b0d5VDFKQzBtTUV2alhROS1wS2R4ZFh0OHpPaTQyYnU3SmpMWmRhSXo2Wkx1UEtWRFdFTFZPX08tTzZJUk9hSHBWSkxtdl…
Fund Update: New $8.3M $LYG stock position opened by BI Asset Management Fondsmaeglerselskab A|S - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPVEtzek1pS2JVYVZjZHFHSW1lQnNTRlNSUWg4YUJIcXVfWjVnZ0NOU1h3Yk1lR3AtZlNTQ0tEQlB6WVdxTEQtejdRQmU3YkFRSVJDbTRUNkRybWFNQVhNamNJQmRPdW84bU9HLTVvVHEtQXY4blk4NzhiVXVRUDZGTkJzdk1rYmpzT0c0TD…
China’s CSI 300 Set to Lose Appeal Before Adding CXMT, BI Says - Bloomberg.com
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOUmFlWTlTcm9Oa3l3aWRPWHcwcDJBYVhHVGZNT21vRk1xRDJtUFN0U25zZDdHT2pwaFM5Nkw5T3VpVjZPdC1XNWdSMnBIUDZUNEdaT010MU9LN0gwbHRLVlFrYU9jR3JSN3RrMnZxUTZCSGlVVGhyZjJMb243M2xHSGdDSzV6NnBYMTdoOW…
Why Michael Saylor's Strategy decided to make STRC's dividend bi-monthly - CoinDesk
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPbFdqdmM1YmpmSng5NEVpTzBhc3hISERMcjVLQWthOWNPMEtILTBZY09rZVp6RFZoZ3F6OEo5M2tjb3d2VHpmM0hFclI5R3JsZHBUSldqWnZ2X3RneWFUWnJxbFZHWEpmeXd6UDhNV1hCYjFGNDNUMll3RFNKaXE0RG56dkZIRjZrMldUMC…
BI — Frequently Asked Questions
What is the current share price of Bilcare Limited (BI)?
As of 2026-09-08 04:53 IST, Bilcare Limited (BI) trades at ₹95.85 on NSE. Its 52-week range is ₹56.18 to ₹101.38.
What is the P/E ratio of BI?
BI trades at a trailing price-to-earnings (P/E) ratio of 131.30. Its price-to-book (P/B) ratio is 0.75.
What is the return on equity (ROE) of BI?
BI has a return on equity (ROE) of -8.63%.
Is BI a good stock to buy?
This page provides a data-driven analysis of Bilcare Limited (BI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.